Skip to main content

Targeted Therapies

Call for papers: Targeted Therapies for Cancer

Guest-edited by:  Prof. Min Li, University of Oklahoma Health Sciences Center (OUHSC), USA
                             Dr. Yanis Boumber, Robert H Lurie Comprehensive Cancer Center, Feinberg                                     School of Medicine, Northwestern University, Chicago, USA 

New Content Item

Over the past two decades, significant progress has been made in understanding the molecular mechanisms of cancer, which has led to the development of molecular targeted agents including tyrosine kinase inhibitors, antiangiogenic agents, cell cycle and signalling targeting compounds, PARP inhibitors, DNA methylation inhibitors and antibody-drug conjugates. For many cancers including leukaemia, melanoma, lung, colorectal and breast cancer, targeted therapies have transformed the repertoire of currently available treatments, such as Vemurafenib for BRAF mutated metastatic melanoma and Herceptin for HER2 overexpressing breast cancer. Yet, the responses to targeted therapies are only marginal and short-lived, since many cancers develop resistance leading to disease progression, in addition to patients experiencing toxic side effects and financial burdens associated with treatment.

To overcome the problems associated with tumour resistance, research is focused on developing combination strategies involving targeted therapies and next-generation inhibitors with enhanced efficacy and selectivity. At the same time, molecular approaches are warranted to identify biomarkers and select the most suitable patients to optimise benefit and minimise toxicity.

In recognition of the growing field of research, BMC Medicine and BMC Cancer come together to invite submissions of original research including but not limited to:

  • Novel molecular targeted therapies, such as small molecules, antibodies and drug-antibody conjugates for new tumour targets
  • Resistance to conventional targeted therapies or the development of novel therapeutic targets that overcome targeted therapy resistance
  • Combination therapies involving targeted therapy
  • Discovery of novel serum/tumor biomarkers relevant to targeted therapies in clinical cohorts (e.g. from clinical trials)
  • Identification of genomic biomarkers relevant to targeted therapies in bioinformatics analyses (Please note: the presented biomarkers must have been validated in at least 2 independent validation cohorts)
  • Survivorship and toxicology in patients treated with targeted or combination therapy regimens

For more information about each participating journal, including article-processing charges, click on its title below. After submitting to a participating journal, each article will undergo that journal’s full standard peer review process.

BMC Medicine encourages submissions of front matter articles and original research including randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), clinical retrospective or prospective “Real World” studies, cost-effectiveness analysis, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. For translational research we only consider studies that include patients or involves human samples. BMC Medicine does not consider case reports.

Guest Editors provided guidance on the scope of this collection and advised on commissioned content. However, they are not involved in editorial decision-making on papers submitted to this collection. All final editorial decisions are with the Editor-in-Chief, Dr. Lin Lee.​

BMC Cancer encourages submissions of original research and  study protocols reporting on randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), prospective “Real World” studies, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. BMC Cancer does not consider case reports. For pre-clinical and experimental research, we only consider studies that provide results validated in at least 3 relevant cell lines, preferably validated in at least one animal model.  Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered.

To submit to BMC Medicine please click here. See also our journal submission guidelines.
To submit to BMC Cancer please click here. See also our journal submission guidelines.

For pre-submission enquiries for the collection please contact Editorial Office (for BMC Medicine) or Linda Gummlich (for BMC Cancer).

We advise to submit by 1st August 2021 if you would like your manuscript to be ready for the launch date. After launch, the collection will remain open and accept submissions for one year.

Min Li

New Content ItemDr. Min Li is Professor of Medicine, Surgery, and Cell Biology at The University of Oklahoma Health Sciences Center (OUHSC), and holds the George Lynn Cross Research Professorship and the Virginia Kerley Cade Endowed Chair in Cancer Treatment. He is the Assistant Dean for International Research Collaboration at College of Medicine, and Associate Director for Global Oncology at the NCI designated Stephenson Cancer Center (SCC). He is also Director of GI Cancer Research, and Vice Chair for Research at the Department of Surgery, and Co-Leader of Cancer Biology Program of SCC at OUHSC. He is a leading expert on pancreatic cancer (PC), and his research mainly focus on studying PC and brain tumor pathogenesis and developing new therapies. Dr. Li’s group is the first to identify a key zinc transporter ZIP4, which is aberrantly expressed in PC, and promotes cancer growth, cachexia, and metastasis. He has published more than 180 papers and has 3 active NIH R01 grants, and multiple private foundation grants. 

Dr. Li is the council member of the International Association for Pancreatology (IAP), and councilor of the American Pancreatic Association (APA). He will be the President of APA in 2022. He received many awards such as the Outstanding Achievement Award of IAP, and the Provost Research Award. He is an Editorial Advisor for BMC Medicine

Yanis Boumber

New Content ItemYanis Boumber, MD, PhD, Associate Professor, Division of Hematology/ Oncology, Section of Thoracic Head and Neck Medical Oncology, at Northwestern University Cancer Center in Chicago. Dr. Boumber has previously worked as Assistant Professor in the Thoracic Section of the Department of Hematology/Oncology at the Fox Chase Cancer Center, Philadelphia, USA.

Dr Boumber graduated from the Rostov State Medical University, Russia and qualified as MD in 1999. He received his PhD in cancer biology and molecular biology at the University of Texas MD Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences in Houston in 2005. He completed his medicine residency at Good Samaritan hospital, affiliated with Johns Hopkins University in Baltimore in 2010, and medical oncology and hematology fellowship at the University of Texas MD Anderson Cancer Center in 2013.

His research interests include the investigation of signaling pathways and biological processes controlled by MSI2 and developing novel therapeutic approaches to target MSI2 in lung cancer. He joined the editorial board of BMC Cancer in 2016 as Deputy Section Editor. He serves as Senior Board Member since August 2020.

There are currently no articles in this collection.